↓ Skip to main content

Phytocannabinoids

Overview of attention for book
Attention for Chapter 3: Molecular Pharmacology of Phytocannabinoids
Altmetric Badge

Mentioned by

news
5 news outlets
twitter
4 X users
patent
1 patent
wikipedia
1 Wikipedia page

Citations

dimensions_citation
44 Dimensions

Readers on

mendeley
323 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Molecular Pharmacology of Phytocannabinoids
Chapter number 3
Book title
Phytocannabinoids
Published in
Progress in the chemistry of organic natural products, January 2017
DOI 10.1007/978-3-319-45541-9_3
Pubmed ID
Book ISBNs
978-3-31-945539-6, 978-3-31-945541-9
Authors

Turner, Sarah E., Williams, Claire M., Iversen, Leslie, Whalley, Benjamin J., Sarah E. Turner, Claire M. Williams, Leslie Iversen, Benjamin J. Whalley

Abstract

Cannabis sativa has been used for recreational, therapeutic and other uses for thousands of years. The plant contains more than 120 C21 terpenophenolic constituents named phytocannabinoids. The Δ(9)-tetrahydrocannabinol type class of phytocannabinoids comprises the largest proportion of the phytocannabinoid content. Δ(9)-tetrahydrocannabinol was first discovered in 1971. This led to the discovery of the endocannabinoid system in mammals, including the cannabinoid receptors CB1 and CB2. Δ(9)-Tetrahydrocannabinol exerts its well-known psychotropic effects through the CB1 receptor but this effect of Δ(9)-tetrahydrocannabinol has limited the use of cannabis medicinally, despite the therapeutic benefits of this phytocannabinoid. This has driven research into other targets outside the endocannabinoid system and has also driven research into the other non-psychotropic phytocannabinoids present in cannabis. This chapter presents an overview of the molecular pharmacology of the seven most thoroughly investigated phytocannabinoids, namely Δ(9)-tetrahydrocannabinol, Δ(9)-tetrahydrocannabivarin, cannabinol, cannabidiol, cannabidivarin, cannabigerol, and cannabichromene. The targets of these phytocannabinoids are defined both within the endocannabinoid system and beyond. The pharmacological effect of each individual phytocannabinoid is important in the overall therapeutic and recreational effect of cannabis and slight structural differences can elicit diverse and competing physiological effects. The proportion of each phytocannabinoid can be influenced by various factors such as growing conditions and extraction methods. It is therefore important to investigate the pharmacology of these seven phytocannabinoids further, and characterise the large number of other phytocannabinoids in order to better understand their contributions to the therapeutic and recreational effects claimed for the whole cannabis plant and its extracts.

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 323 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Italy 1 <1%
Unknown 322 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 55 17%
Student > Ph. D. Student 46 14%
Student > Bachelor 43 13%
Student > Master 26 8%
Other 16 5%
Other 36 11%
Unknown 101 31%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 46 14%
Biochemistry, Genetics and Molecular Biology 45 14%
Medicine and Dentistry 26 8%
Chemistry 25 8%
Agricultural and Biological Sciences 21 7%
Other 45 14%
Unknown 115 36%